A Washington Post investigation revealed secret drug-pricing deals between the Trump administration and Eli Lilly.
The agreements reportedly offered Eli Lilly protection from tariffs in exchange for raising drug prices overseas.
The Department of Health and Human Services used broad confidentiality clauses to exempt the deal terms from Freedom of Information Act (FOIA) requests.
Records obtained through FOIA lawsuits show that key terms remained unresolved even as the administration publicly promoted the agreements.